10-Q: Limitless X Reports Steep Q2 Loss Amid Revenue Decline
Quarterly Report
Limitless X Holdings Inc. reported a significant increase in net loss for the second quarter and first half of 2025, driven by sharp revenue declines and substantial non-cash losses from debt conversions.
Summary
- Net loss for the six months ended June 30, 2025, surged to $39.2 million, a 2164.7% increase from $1.7 million in the prior year.
- Product sales plummeted by 77.2% to $0.55 million for the six months ended June 30, 2025, compared to $2.43 million in the same period last year, attributed to shifts in marketing and selling strategies.
- Operating expenses increased by 63.9% to $5.36 million, primarily due to $3.3 million in stock compensation expense.
- A substantial non-cash loss of $33.8 million was recognized from the settlement of debt through the conversion of loans payable to shareholders and related parties into preferred stock.
- The company's accumulated deficit reached approximately $78.1 million as of June 30, 2025.
- Cash balance increased to $85,175 at June 30, 2025, from $53,549 at December 31, 2024, supported by $1.96 million in financing activities.
- The company provided a new loan receivable of $1.0 million to a third party, extended to September 15, 2025.
Sentiment
Score: 1
Explanation: The company is in a highly precarious financial position, marked by a massive net loss, severe revenue decline, substantial accumulated deficit, and explicit going concern doubt. The reliance on dilutive debt-to-equity conversions and related-party financing indicates significant financial distress and an unsustainable business model in its current form.
Positives
- Cash balance increased to $85,175 at June 30, 2025, from $53,549 at December 31, 2024.
- Successfully raised $1.96 million through borrowings from a stockholder and related parties during the six months ended June 30, 2025.
- Reduced accounts payable and accrued expenses from $6.02 million to $3.22 million, and accrued interest from $1.04 million to $0.085 million, largely due to debt conversions.
Negatives
- Net loss for the six months ended June 30, 2025, increased by 2164.7% to $39.2 million from $1.7 million in the prior year.
- Product sales decreased by 77.2% to $0.55 million for the six months ended June 30, 2025, from $2.43 million in the prior year.
- Gross profit declined by 80.2% to $0.35 million for the six months ended June 30, 2025, from $1.77 million in the prior year.
- Operating expenses increased by 63.9% to $5.36 million, driven by significant stock compensation expense.
- Incurred a substantial non-cash loss of $33.8 million on debt settlement due to the conversion of loans into preferred stock.
- Accumulated deficit grew to $78.1 million as of June 30, 2025.
- Net cash used in operating activities increased to $0.92 million for the six months ended June 30, 2025, from $0.69 million in the prior year.
- Significant dilution from the issuance of 6.95 million new common shares and various preferred stock classes (Class C, Class D, Class D Issuable) for debt conversion and services.
Risks
- Substantial doubt about the company's ability to continue as a going concern due to significant accumulated deficit and net losses.
- Dependence on raising additional capital to fund future operations, with no assurance that such financing can be obtained.
- Increasingly competitive industry conditions may negatively impact results of operations and cash flows.
- Material weakness in internal control over financial reporting due to insufficient personnel, leading to inadequate segregation of duties and independent review, which could result in material misstatements.
- Reliance on a few suppliers, with one largest supplier accounting for 99% of total purchases.
- Risk of non-payment from customers, although currently considered minimal.
- Risks associated with third-party payment gateway settlers, including reserve fees and potential for losses from processing bank failures.
Future Outlook
The company explicitly states that its ability to continue as a going concern is in substantial doubt and it needs to raise additional capital to fund future operations, with no assurance that such financing can be obtained. It also acknowledges that increasingly competitive industry conditions may negatively impact its results and cash flows.
Management Comments
- Management is of the opinion that legal actions and claims arising in the normal course of business will be resolved without material effect on the company's financial condition or results of operations.
- Management believes that the hiring of additional personnel who have the technical expertise and knowledge with the non-routine or technical issues we have encountered in the past will result in both proper recording of these transactions and a much more knowledgeable finance department as a whole.
- Additional personnel will also ensure the proper segregation of duties and provide more checks and balances within the department.
- We will continue to monitor and evaluate the effectiveness of our disclosure controls and procedures and our internal controls over financial reporting on an ongoing basis and are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.
Industry Context
The company operates as a lifestyle brand in the health and wellness industry, focusing on nutritional supplements and digital marketing services. Its significant decline in product sales and gross profit, coupled with substantial losses, suggests a struggle to adapt to or compete within the increasingly competitive digital marketing and health product sectors. The shift in marketing and selling strategies and changes in performance marketers indicate challenges in maintaining market presence and sales effectiveness compared to broader industry trends that often see growth in these sectors.
Comparison to Industry Standards
- The company's product sales decline of 77.2% for the six months ended June 30, 2025, is significantly worse than typical growth rates in the health and wellness or digital marketing industries, which generally experience positive growth. For example, many direct-to-consumer health supplement companies or digital marketing agencies would aim for double-digit revenue growth, not steep declines.
- The gross profit margin decreased from 73.0% to 63.2%, while still relatively high, the significant drop indicates potential issues with product pricing, cost of goods, or increased returns/chargebacks, which could be below best-in-class industry benchmarks.
- The accumulated deficit of $78.1 million and a net loss of $39.2 million for six months are indicative of a company far from profitability and sustainable operations, contrasting sharply with established, profitable companies in the sector like GNC Holdings (though private now) or publicly traded digital marketing firms that demonstrate consistent earnings.
- The reliance on debt conversions into preferred stock at terms leading to massive non-cash losses ($33.8 million) suggests a distressed financial situation, unlike financially stable industry peers who can access traditional, less dilutive financing.
- The identified material weakness in internal controls over financial reporting is a significant governance issue, placing the company below the standards expected of publicly traded entities, especially compared to larger, well-governed companies in the consumer health or tech sectors.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weakness | Identified a material weakness in internal control over financial reporting due to insufficient personnel, leading to inadequate segregation of duties and independent review of financial statements. | 2025-06-30 | This deficiency creates a reasonable possibility that material misstatements will not be prevented or detected on a timely basis, impacting financial reporting reliability. |
Related Party Transactions
- Royalty payables of $249,036 as of June 30, 2025, to Licensors (Limitless Performance Inc., SMILZ INC., DIVATRIM INC., AMAROSE INC.) which are at least 50% owned by a company shareholder.
- Notes payable to a shareholder (Chief Executive Officer) totaling $5,144,460 as of December 31, 2024, were converted to preferred C and D shares during the six months ended June 30, 2025.
- Notes payable to other related parties increased to $1,180,000 as of June 30, 2025, from $436,747 as of December 31, 2024. Some of these were converted to preferred C shares.
- A $1,000,000 loan was provided by EM1 Capital (a related party) on January 24, 2025, at 12.5% interest, extended to September 2025.
- EM1 Capital (a related party) provided additional loans of $25,000 on June 9, 2025, and $75,000 on June 11, 2025, both at 15% interest, due December 9 and 11, 2025, respectively.
- Issuance of 260,214 Class D Convertible Preferred Stock shares to related parties on April 14, 2025 (issued July 18, 2025), valued at $6,505,350.
- Issuance of 520,000 common shares to related parties on July 22, 2025, for settlement of $250,000 debt.
Stakeholder Impact
- Shareholders face significant dilution due to massive issuance of common and preferred stock for debt conversion and services, leading to substantial value erosion.
- Creditors (specifically shareholders and related parties) converted debt into preferred stock, indicating a restructuring of liabilities but also a potential loss on the original debt value as reflected in the 'loss on debt settlement'.
- Employees received common stock as compensation and for settlement of accrued wages, which could be a positive for those receiving shares but also indicates cash flow constraints for wage payments.
- Customers may experience issues with product availability, marketing effectiveness, or satisfaction given the significant decline in product sales.
- Suppliers may face payment issues as vendor debt was settled with common stock and preferred C stock, rather than cash.
Next Steps
- Raise additional capital to fund future operations.
- Hire additional personnel for accounting and financial reporting functions to address material weakness in internal controls.
- Continue to monitor and evaluate the effectiveness of disclosure controls and internal controls over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2020-01-15 | The 2020 Stock Incentive Plan was adopted. |
| 2021-03-01 | Prime Time Live, Inc. received an unsecured promissory note of $35,000 at 10% interest, initially due March 1, 2022. |
| 2021-12-01 | The company entered into manufacturing and distributorship license agreements with Licensors (LPI, SMILZ INC., DIVATRIM INC., AMAROSE INC.). |
| 2021-12-06 | The company entered into a Loan Authorization and Agreement for a $50,000 loan from a shareholder. |
| 2022-02-11 | The company entered into a Loan Authorization and Agreement for a $150,000 loan from a shareholder. |
| 2022-05-08 | The company entered into a Loan Authorization and Agreement for a $550,000 loan from a shareholder. |
| 2022-05-10 | Related parties loaned Prime Time Live, Inc. $12,500, $12,500, and $20,000 respectively. |
| 2022-05-11 | Bio Lab Naturals, Inc. entered into a Share Exchange Agreement with Limitless X, Inc. and its shareholders. |
| 2022-05-16 | The company entered into a Loan Authorization and Agreement for a $1,100,000 loan from a shareholder. |
| 2022-05-18 | The company entered into a Loan Authorization and Agreement for a $450,000 loan from a shareholder. |
| 2022-05-20 | The LimitlessX Acquisition closed; Bio Lab issued 3,233,334 common shares to LimitlessX shareholders, and Jaspreet Mathur purchased 500,000 Class A Preferred Convertible Stock shares. |
| 2022-05-31 | Related parties loaned Prime Time Live, Inc. $5,000 and $15,000 respectively. |
| 2022-06-01 | The company entered into a Loan Authorization and Agreement for a $500,000 loan from a shareholder. |
| 2022-06-09 | The company loaned a shareholder $15,000. |
| 2022-06-10 | Bio Lab changed its name to Limitless X Holdings Inc. |
| 2022-06-30 | The company entered into a Loan Authorization and Agreement for a $922,028 loan from a shareholder. |
| 2022-08-09 | The 2022 Incentive and Non-statutory Stock Option Plan and 2022 Restricted Stock Plan were adopted. |
| 2022-08-25 | The company entered into a Loan Authorization Agreement for a $290,000 loan from a shareholder. |
| 2022-11-15 | The company entered into a Loan Authorization and Agreement for a $450,000 loan from a shareholder. |
| 2023-05-04 | The 2020 Stock Incentive Plan was terminated. |
| 2023-05-16 | The company entered into a Loan Authorization and Agreement for a $150,000 loan from a shareholder. |
| 2023-05-18 | The company entered into a Loan Authorization and Agreement for a $50,000 loan from a shareholder. |
| 2023-06-03 | The company entered into a Funding Commitment Agreement with its Chief Executive Officer and Chairman of the Board of Directors, Jaspreet Mathur. |
| 2023-06-05 | The company entered into a Loan Authorization and Agreement for a $150,000 loan from a shareholder. |
| 2023-06-20 | A $50,000 drawdown occurred under the Funding Commitment Agreement. |
| 2023-07-01 | Maturity date for the $500,000 loan from a shareholder (June 1, 2022 loan). |
| 2023-07-13 | A $50,000 drawdown occurred under the Funding Commitment Agreement. |
| 2023-08-01 | A $190,000 drawdown occurred under the Funding Commitment Agreement; also maturity date for the $922,028 loan from a shareholder (June 30, 2022 loan). |
| 2023-08-07 | A $50,000 drawdown occurred under the Funding Commitment Agreement. |
| 2023-10-01 | The company terminated most License Agreements, maintaining only the NZT-48 license with LPI. |
| 2023-10-23 | The company issued 10,349,097 shares of Class B Preferred Stock, extinguishing $9,675,000 of convertible debt. |
| 2024-03-12 | Emblaze One (related party) provided a $419,428 loan; EM1 Capital (related party) provided a $100,000 loan. |
| 2024-03-15 | Emblaze One (related party) provided a $419,428 loan. |
| 2024-03-27 | EM1 Capital (related party) provided a $100,000 loan. |
| 2024-04-22 | EM1 Capital (related party) provided a $49,139 loan. |
| 2024-04-26 | EM1 Capital (related party) provided a $45,000 loan. |
| 2024-06-25 | EM1 Capital (related party) provided a $32,000 loan. |
| 2024-06-28 | EM1 Capital (related party) provided a $25,000 loan. |
| 2024-07-31 | The company entered into a $360,000 loan payable agreement. |
| 2024-08-14 | The company's Quarterly Report on Form 10-Q was filed with the SEC (referenced in Exhibit 3.1). |
| 2024-09-09 | Class B shareholders converted 9,286,385 shares of Class B Preferred Stock into 311,100 common stock shares. |
| 2024-09-10 | Form of Settlement Agreement and Release of Claims between the company and certain employees (referenced in Exhibit 10.1). |
| 2024-09-16 | The company's Quarterly Report on Form 8-K was filed with the SEC (referenced in Exhibit 10.1). |
| 2024-09-26 | The company's Form 8-K was filed with the SEC (referenced in Exhibit 3.2). |
| 2024-12-31 | End of fiscal year for the 2024 Annual Report on Form 10-K. |
| 2025-01-02 | Certification of Designation of Class C Convertible Preferred Stock was filed. |
| 2025-01-23 | Certification of Designation of Series D 15% Cumulative Redeemable Perpetual Preferred Stock was filed. |
| 2025-01-24 | The company provided a $1,000,000 loan to a third-party; EM1 Capital (related party) provided a $1,000,000 loan. |
| 2025-03-21 | The company entered into a Loan Authorization and Agreement for a $500,000 loan from a shareholder. |
| 2025-03-23 | A $500,000 shareholder loan was made. |
| 2025-03-24 | Emblaze One (related party) provided a $163,515 loan; EM1 Capital (related party) provided a $1,000,000 loan. |
| 2025-04-10 | 10,000 preferred C shares and 225,000 common stock shares were issued under the March 21, 2025 loan agreement. |
| 2025-04-14 | The company entered into a Class D Convertible Preferred Stock agreement to issue 260,214 shares to related parties. |
| 2025-05-09 | The company's 2024 Annual Report on Form 10-K was filed with the SEC. |
| 2025-05-31 | The $35,000 unsecured promissory note's maturity date was extended to this date. |
| 2025-06-09 | EM1 Capital (related party) provided a $25,000 loan. |
| 2025-06-11 | EM1 Capital (related party) provided a $75,000 loan. |
| 2025-06-12 | The company entered into a consulting agreement to issue 600,000 restricted common shares. |
| 2025-06-30 | End of the current reporting period for the Form 10-Q. |
| 2025-07-11 | Related to $250,000 debt settled on July 22, 2025. |
| 2025-07-16 | The company issued 740,000 common shares from conversion of Class C shares. |
| 2025-07-18 | 260,214 Class D Convertible Preferred Stock shares were issued to related parties. |
| 2025-07-21 | The company issued 100,000 common shares to a consultant for a sponsorship agreement. |
| 2025-07-22 | The company issued 520,000 common shares to related parties for settlement of $250,000 debt. |
| 2025-07-31 | Maturity date for the $360,000 loan payable agreement. |
| 2025-08-13 | Latest practicable date for common stock outstanding (16,900,256 shares). |
| 2025-08-14 | Date of filing for the Form 10-Q. |
| 2025-09-15 | Extended maturity date for the $1,000,000 loan receivable provided by the company. |
| 2025-09-01 | Extended maturity date for the $1,000,000 loan from EM1 Capital (related party). |
| 2025-11-11 | Maturity date for the $105,000 loan payable agreement. |
| 2025-12-09 | Maturity date for the $25,000 loan from EM1 Capital (related party). |
| 2025-12-11 | Maturity date for the $75,000 loan from EM1 Capital (related party). |
Recommendation
strong sellThe company's financial performance is in severe decline, marked by a staggering 77.2% drop in revenue and a net loss exceeding $39 million for the first half of 2025. The accumulated deficit of over $78 million and the explicit 'going concern' warning indicate a high risk of bankruptcy or further significant dilution. The reliance on converting related-party debt into highly dilutive preferred and common stock, resulting in a $33.8 million non-cash loss on debt settlement, signals extreme financial distress and an unsustainable capital structure. The identified material weakness in internal controls further undermines investor confidence. Given the dire financial state, lack of clear path to profitability, and ongoing dilution, a strong sell recommendation is warranted to avoid further capital loss.
Keywords
Health and Wellness, Digital Marketing, Nutritional Supplements, Performance Marketing, SEC Filing, Quarterly Report, Going Concern, Debt Conversion, Preferred Stock, Stock Compensation, Financial Performance, Losses, Revenue Decline, Internal Controls, Related Party Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.